Newron Pharmaceuticals S.p.A. (NP5.DE) XETRA
14.20
-0.05(-0.35%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
14.20
-0.05(-0.35%)
Currency In EUR
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
July 04, 2019
| Name | Title | Pay | Year Born |
| Stefan Weber | Chief Executive Officer & Executive Director | 483,000 | 1965 |
| Ravi Anand | Chief Medical Officer | 1.34M | 1957 |
| Filippo Moriggia | Vice President of Operations | 0 | N/A |
| Roberto Galli | Chief Financial Officer | 0 | N/A |
| Laura Faravelli | Vice President of Business Development | 0 | N/A |
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 24 full-time employees. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.